SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: margie who wrote (1894)9/30/1997 4:43:00 AM
From: Henry Niman   of 6136
 
margie, Actually, AGPH's press release also lends some credence to the paper discussed in thestreet. Patients that had previously failed other treatments and then failed Viracept treatment didn't do well when switched to another PI (4 of 7 failed to see viral loads reduced to 500 copies/mL):
" Dr. Henry will also report that viral load
fell below 500 copies/mL in three of seven patients in a second group of extensively pre-treated
patients (all of those tested were resistant to 3TC) from another VIRACEPT clinical trial who were
switched to the regimen containing ritonavir, saquinavir, d4T and 3TC. At baseline, the mean viral
load in these seven patients was 263,027; mean CD4+ T cell count was 65.(3) "

From the two studies it seems clear that patients who have been treated extensively before a PI is introduced, don't do all that well even when the first PI is Viracept. Thus patients with a resistance problem will do poorly when a PI is introduced, and they will also do poorly when the PI is switched.

Therefore, my question really centers on an apples to apples comparision. AGPH's recent data indicates that naive patients started on Viracept do well when they are switched to another PI after they become resistant to Viracept. Has a lack of success been shown when naive patients are switched to another PI (Viracept?) after developing resistance to a PI other than Viracept (in vivo, not in vitro)?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News